ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.

The Centers for Disease Control and Prevention (CDC) and seven US pediatric medical centers report a notable association ...

Young children and infants with asthma symptoms/acute wheeze may benefit from treatment with inhaled short-acting β2-agonists (SABA).